Publications

Preclinical
World ADC San Diego
November 5, 2025
ZW327 – A Topoisomerase-1 inhibitor ADC Designed to Target Ly6E-Expressing Tumors
Stuart Barnscher
View Publication
Preclinical
SITC
November 8, 2025
TriTCE Co-stim: A differentiated T cell engager platform with conditional cis CD28 co-stimulation and transferability to diverse targeting strategies
Verstraete et al.
View Publication
Preclinical
November 7, 2025
Design of a Next Generation Tumor Targeted Masked IL-12Fc for Enhanced Tolerability and Localized Anti-Tumor Activity
Escalante et al.
View Publication
Preclinical
SITC
November 7, 2025
High-throughput quantitative characterization of cytotoxic antibody-drug conjugates using spheroid models reveals important considerations in potential molecular mechanisms of ADC resistance
Church et al.
View Publication
Preclinical, ZW1528
ERS
September 30, 2025
ZW1528, a Bispecific Antibody Targeting IL-4Rα and IL-33, Potently Inhibits Key Mediators of Airway Inflammation
Hardman et al.
View Publication
Preclinical, ZW1528
World Bispecific Summit
September 10 - September 10, 2025
ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway Inflammation by Inhibiting IL-4Ra and IL-33 Pathways
Alexey Berezhnoy, PhD
View Publication
Preclinical
Immuno-Oncology Summit
August 11, 2025
Engineering TrispecificT Cell Engager Leveraging Conditional CD28 Co-Stimulation to Treat Solid Tumors
Genevieve Desjardins, PhD
View Publication
Preclinical
T cell Engager Summit
June 26, 2025
ZW209: A DLL3 Targeted Trispecific T Cell Engager with Conditional and Obligate cis CD28 Co-stimulation to Improve Responses in DLL3-Expressing Tumors
Nina Weisser, PhD
View Publication
Preclinical, ZW1528
ATS
May 19, 2025
ZW1528, a Bispecific Antibody Targeting IL-4Rα and IL-33, Potently Inhibits Key Mediators of Airway Inflammation
Poffenberger et al.
View Publication
Preclinical
Festival of Biologics
April 23, 2025
Trispecific T Cell Engagers Incorporating Conditional CD28 Co-Stimulation (TriTCE Co-Stim) to Improve Treatment Responses in Oncology
Chayne Piscitelli
View Publication
Preclinical
AACR
April 30, 2025
ZW209, a DLL3 targeted trispecific T cell engager with integrated CD28 co-stimulation, demonstrates safety and potent preclinical efficacy in models of small cell lung cancer
Lau et al.
View Publication
Preclinical
AACR
April 29, 2025
In vitro assays for prediction of ADC hematological toxicity: contribution of antibody, linker, and payload
Colombo et al.
View Publication